Endocrine Abstracts

Introduction: Primary aldosteronism (PA) is a major cause of secondary hypertension. The two major forms of sporadic PA (aldosterone producing adenoma – APA and bilateral adrenal hyperplasia – BAH) can only be reliably differentiated by adrenal venous sampling (AVS). Several mutations have been described for APA, but the pathogenesis of BAH is poorly elucidated. Differentiation of APA and BAH is clinically pivotal, as their treatment is different. There is no blood-b...

Poor agreement between different analytical methods measuring aldosterone concentrations impedes applicability of uniform cut-offs in the diagnostic work-up of primary aldosteronism (PA). We compared 4 analytical methods (2 immunoassays and 2 LC-MS/MS) in plasma samples before and after saline infusion test (SIT). 80 hypertensive patients underwent the standardized diagnostic work-up within the German Conn’s registry. Patients (PA n=39/non-PA n=41) were ...

Background: Primary aldosteronism (PA) is a secondary form of arterial hypertension that – in case of unilateral disease – can be cured by surgery. Multiple studies have shown that PA patients are at higher risk to suffer from cardiovascular events and to develop metabolic diseases. Two thirds of patients with PA suffer from obstructive sleep apnea (OSA). A bi-directional, pathophysiological interplay between OSA and PA has been proposed, with focus on overnight ro...

Introduction: Primary aldosteronism (PA) is the most common surgically curable cause for endocrine hypertension. Patients with unilateral aldosterone-producing adenoma undergo adrenalectomy (ADX). Clinical and biochemical outcome is assessed 6-12 months after ADX according to PASO consensus. To reduce unnecessary follow-up visits and change in medication for diagnostic purposes for potentially cured patients after ADX, a prediction tool is needed. Previous research had shown g...

Rationale: Endothelial dysfunction (ED) is a hallmark of primary aldosteronism and paves the way for subsequent atherosclerotic disease. Past research has confirmed that one factor involved in ED is disturbed nitric oxide (NO) signalling. Since defects in NO release alone cannot explain the whole effect, we set out to address the role of endothelial CYP-expoygenase products (epoxyeicosatrienoic acids, EETs) in aldosterone-mediated endothelial dysfunction.<p class="abstext"...